First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that stimulates CD8(+) T-cell and natural killer (NK) cell antitumor responses, and we hypothesized this cytokine may a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Romee, Rizwan, Cooley, Sarah, Berrien-Elliott, Melissa M., Westervelt, Peter, Verneris, Michael R., Wagner, John E., Weisdorf, Daniel J., Blazar, Bruce R., Ustun, Celalettin, DeFor, Todd E., Vivek, Sithara, Peck, Lindsey, DiPersio, John F., Cashen, Amanda F., Kyllo, Rachel, Musiek, Amy, Schaffer, András, Anadkat, Milan J., Rosman, Ilana, Miller, Daniel, Egan, Jack O., Jeng, Emily K., Rock, Amy, Wong, Hing C., Fehniger, Todd A., Miller, Jeffrey S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992862/
https://ncbi.nlm.nih.gov/pubmed/29463563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-823757
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados